INT90679

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2000
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 11.62
Pain Relevance 0.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 6
SGC 1
arm 1
Hivan1 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 38 88.32 High High
chemokine 20 87.20 High High
abdominal pain 4 86.40 High High
nud 2 84.08 Quite High
Bile 39 73.88 Quite High
headache 15 72.24 Quite High
agonist 11 71.76 Quite High
Bioavailability 4 63.00 Quite High
antagonist 45 57.04 Quite High
withdrawal 8 29.64 Quite Low
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 955 100.00 Very High Very High Very High
Infection 111 99.36 Very High Very High Very High
Hyperlipidemia 5 98.44 Very High Very High Very High
Cardiovascular Disease 1 96.04 Very High Very High Very High
Primary Sclerosing Cholangitis 3 91.92 High High
Brain Tumor 6 89.84 High High
Disease 75 88.68 High High
Vomiting 66 87.92 High High
Cognitive Disorder 39 87.84 High High
Diarrhoea 22 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The median CSF HIV-1 RNA was reduced, albeit by a modest 0.64 log10 copies/mL over the 12 wk and ABC was present in the CSF in potentially efficacious concentrations, on average 9-fold greater than the IC50 reported for ABC for the wild-type virus.
Negative_regulation (reduced) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
1) Confidence 0.07 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.53 Pain Relevance 0
A number of antiretroviral drugs may be effective in the treatment of ADC, based upon reduction of HIV-1 RNA in the CSF, as seen with stavudine (d4T), lamivudine (3TC) [9], and indinavir [10]; the measurement of potentially efficacious drug concentrations in the CSF, as observed with nevirapine and efavirenz [11,12]; and efficacy in in vitro models (d4T, 3TC, and efavirenz) [13].
Negative_regulation (reduction) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
2) Confidence 0.07 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.48 Pain Relevance 0
The latter participants had less reduction in plasma HIV-1 RNA compared to those with virus with two or fewer mutations.
Negative_regulation (reduction) of HIV-1 in plasma associated with acquired immune deficiency syndrome or hiv infection
3) Confidence 0.05 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.28 Pain Relevance 0
If the median reductions in CSF HIV-1 RNA from baseline are estimated using week 12 data (or using week 6 data if week 12 value is missing), the median HIV-1 RNA reduction for the ABC + SBG group of ?
Negative_regulation (reduction) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
4) Confidence 0.05 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.81 Pain Relevance 0
Due primarily to low HIV-1 RNA copy number, only 67 baseline plasma samples and 26 baseline CSF samples were successfully genotyped.
Negative_regulation (number) of HIV-1 in plasma associated with acquired immune deficiency syndrome or hiv infection
5) Confidence 0.05 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.64 Pain Relevance 0
Lanier et al. have shown in a meta-analysis of five studies where ABC was added to existing therapy that there was significant reduction in plasma HIV viral load even in patients with baseline NRTI mutations as long as the number of these did not exceed four [27].
Negative_regulation (reduction) of HIV in plasma associated with acquired immune deficiency syndrome or hiv infection
6) Confidence 0.05 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.73 Pain Relevance 0
If the median reductions in CSF HIV-1 RNA from baseline are estimated using week 12 data (or using week 6 data if week 12 value is missing), the median HIV-1 RNA reduction for the ABC + SBG group of ?
Negative_regulation (reductions) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
7) Confidence 0.05 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1845158 Disease Relevance 0.76 Pain Relevance 0
In contrast, PMA-induced downregulation of the HIV-1 receptor CD4 was independent of ESCRT-I and Vps4; HIV-1 Gag had no effect on this process.


Negative_regulation (downregulation) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
8) Confidence 0.02 Published 2008 Journal Virol J Section Abstract Doc Link PMC2262066 Disease Relevance 0.69 Pain Relevance 0
In this study, we show that HIV-1 Gag, as well as TSG101, differentially affect the kinetics of downregulation of the HIV-1 co-receptors CXCR4 and CD4.
Negative_regulation (downregulation) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
9) Confidence 0.01 Published 2008 Journal Virol J Section Body Doc Link PMC2262066 Disease Relevance 0.51 Pain Relevance 0
As HU selectively depletes a greater number of purine, rather than pyrimidine, nucleotides in vitro [10], theoretically greater inhibition of HIV-1 would be expected with purine analog reverse transcriptase inhibitors, such as ddI [25,26].
Negative_regulation (inhibition) of HIV-1 associated with acquired immune deficiency syndrome or hiv infection
10) Confidence 0.01 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1090576 Disease Relevance 0.31 Pain Relevance 0
Median decrease in HIV-1 RNA from baseline tended to be greater in the HU arm than the non-HU arm at week 24 (-2.10 vs -1.45 log10 copies/mL, P = 0.070), but not week 48 (-2.05 vs -2.12 log10 copies/mL, P = 0.453).
Negative_regulation (decrease) of HIV-1 in arm associated with acquired immune deficiency syndrome or hiv infection
11) Confidence 0.01 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1090576 Disease Relevance 0.58 Pain Relevance 0
On day 14, 54% of subjects in the 8-, 20- and 40-mg/kg groups had plasma HIV-1 RNA reductions of > 1 log10 copies/mL.
Negative_regulation (reductions) of HIV in plasma associated with acquired immune deficiency syndrome or hiv infection
12) Confidence 0.01 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761192 Disease Relevance 0.38 Pain Relevance 0.10
Several phase 1/2a clinical studies have been conducted with maraviroc, which all showed significant reductions in HIV viral load in HIV-infected individuals (Fätkenheuer et al 2005).
Negative_regulation (reductions) of HIV associated with acquired immune deficiency syndrome or hiv infection
13) Confidence 0.01 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761192 Disease Relevance 0.63 Pain Relevance 0.10
In addition, treatment of HIV patients with ritonavir, one of the first commercially available HIV protease inhibitors and a potent SXR activator, can cause hyperlipidemia and may be associated with increased risk of cardiovascular disease [Barbaro, 2006; Carr et al., 1998a; Carr et al., 1998b; Shafran et al., 2005].
Negative_regulation (inhibitors) of HIV associated with cardiovascular disease, acquired immune deficiency syndrome or hiv infection and hyperlipidemia
14) Confidence 0.01 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.81 Pain Relevance 0.07
Individual studies have shown that GM-CSF increases CD4+ T cells counts and may be associated with decreased plasma HIV RNA levels.
Negative_regulation (decreased) of HIV RNA in plasma associated with acquired immune deficiency syndrome or hiv infection
15) Confidence 0.00 Published 2005 Journal J Immune Based Ther Vaccines Section Abstract Doc Link PMC1164429 Disease Relevance 0.76 Pain Relevance 0
P-gp has affinity for a broad range of structurally unrelated large hydrophobic compounds including Vinca alkaloids, epipodophyllotoxins, anthracyclines, cyclosporine A, digoxin, and various HIV protease inhibitors 6–9.
Negative_regulation (inhibitors) of HIV associated with acquired immune deficiency syndrome or hiv infection
16) Confidence 0.00 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792490 Disease Relevance 0.62 Pain Relevance 0.07
Triple therapy with saquinavir SGC plus 2 NRTIs was as effective as nelfinavir-containing triple therapy, or quadruple therapy (saquinavir SGC plus 2 NRTIs plus nelfinavir) in markedly suppressing HIV RNA levels in antiretroviral therapy-experienced or -naive patients.
Negative_regulation (suppressing) of HIV RNA in SGC associated with acquired immune deficiency syndrome or hiv infection
17) Confidence 0.00 Published 2000 Journal Drugs Section Abstract Doc Link 10983742 Disease Relevance 1.15 Pain Relevance 0.13
In antiretroviral therapy-naive and -experienced patients, saquinavir SGC combined with > or =2 nucleoside reverse transcriptase inhibitors (NRTIs), or nelfinavir, or nelfinavir plus 2 NRTIs or nonnucleoside reverse transcriptase inhibitors (NNRTIs), markedly improved immunological and virological surrogate markers (increased mean CD4+ cell counts and decreased mean plasma HIV RNA levels) of HIV infection.
Negative_regulation (decreased) of HIV RNA in plasma associated with acquired immune deficiency syndrome or hiv infection and infection
18) Confidence 0.00 Published 2000 Journal Drugs Section Abstract Doc Link 10983742 Disease Relevance 0.95 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox